OricPharma logoOur bold vision is to develop and commercialize innovative therapies that address cancer resistance, including by making existing therapies work better and longer.
Profound advancements in oncology drug development have expanded the treatment options available to patients, yet therapeutic resistance and relapse continue to limit the efficacy and duration of clinical benefit of such treatments. Cancer resistance continues to be one of the most daunting challenges facing patients, clinicians and researchers in oncology today. At ORIC, our resistance platform is focused on three areas:
Innate
resistance
Acquired
resistance
Bypass
resistance
Clinical trials now enrolling
We are currently enrolling a Phase 1b study of rinzimetostat (ORIC-944) in prostate cancer in combination with AR inhibitors.
We are also enrolling a Phase 1b study of enozertinib (ORIC-114) in NSCLC patients with EGFR exon 20 mutations as a single-agent, in combination with amivantamab and hyaluronidase-lpuj subcutaneous injection (SC amivantamab), and in combination with chemotherapy, as well as in NSCLC patients with EGFR PACC mutations as a single-agent. Do you qualify?
Motivated by a shared purpose
Our collaborative, open culture gives each of us the authority, responsibility and support to do cutting-edge work on therapies for treatment-resistant cancers.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences